About Threshold Pharmaceuticals
Threshold Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib. Evofosfamide is designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not in healthy tissues. Tarloxotinib is under investigation in two Phase II proof-of-concept trials: one for the treatment of patients with mutant EGFR-positive, T790M-negative advanced NSCLC progressing on an EGFR TKI, and the other for patients with recurrent or metastatic squamous cell carcinomas of the head and neck. [18F]-HX4 is an investigational Positron Emission Tomography imaging agent for hypoxia to identify and quantify the degree of hypoxia in tumors in vivo.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: THLD
- CUSIP: 88580720
- Previous Close: $0.60
- 50 Day Moving Average: $0.5532
- 200 Day Moving Average: $0.6386
- 52-Week Range: $71,560,000.00 - $0.22
- Trailing P/E Ratio: 1.0037
- Foreward P/E Ratio: -2.08
- P/E Growth: 0.0000
- Market Cap: $43.24M
- Outstanding Shares: 71,560,000
- Beta: 4.85
- Return on Equity: 101.72%
- Return on Assets: 79.46%
Companies Related to Threshold Pharmaceuticals:
- Current Ratio: 7.96%
- Quick Ratio: 7.96%
What is Threshold Pharmaceuticals' stock symbol?
Threshold Pharmaceuticals trades on the NASDAQ under the ticker symbol "THLD."
Where is Threshold Pharmaceuticals' stock going? Where will Threshold Pharmaceuticals' stock price be in 2017?
1 brokers have issued 12-month target prices for Threshold Pharmaceuticals' stock. Their predictions range from $0.52 to $0.52. On average, they anticipate Threshold Pharmaceuticals' stock price to reach $0.52 in the next twelve months.
When will Threshold Pharmaceuticals announce their earnings?
Threshold Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.
Who owns Threshold Pharmaceuticals stock?
Threshold Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Deerfield Management Co. (3.08%), Renaissance Technologies LLC (0.87%) and FMR LLC (0.56%).
Who sold Threshold Pharmaceuticals stock? Who is selling Threshold Pharmaceuticals stock?
Threshold Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
Who bought Threshold Pharmaceuticals stock? Who is buying Threshold Pharmaceuticals stock?
Threshold Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC.
How do I buy Threshold Pharmaceuticals stock?
Shares of Threshold Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Threshold Pharmaceuticals stock cost?
One share of Threshold Pharmaceuticals stock can currently be purchased for approximately $0.60.